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The elucidation of the mechanisms of transcriptional activation and repression in eukaryotic cells has shed light on the important
role of acetylation-deacetylation of histones mediated by histone acetyltransferases (HATs) and histone deacetylases (HDACs),
respectively. Another group belonging to the large family of sirtuins (silent information regulators (SIRs)) has an (nicotinamide
adenine dinucleotide) NAD+-dependent HDAC activity. Several inhibitors of HDACs (HDIs) have been shown to exert antitumor
eﬀects. Interestingly, some of the HDIs exerted a broad spectrum of antiprotozoal activity. The purpose of this review is to analyze
some of the current data related to the deacetylase enzymes as a possible target for drug development in cancer and parasitic
diseases with special reference to protozoan infections. Given the structural diﬀerences among members of this family of enzymes,
development of speciﬁc inhibitors will not only allow selective therapeutic intervention, but may also provide a powerful tool for
functional study of these enzymes.
Copyright © 2006 M. Ouaissi and A. Ouaissi. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
INTRODUCTION
Regulation of cellular processes by reversible phosphoryla-
tion of key regulatory proteins is fundamental to a large
number of cellular functions. However, during the past few
years, results from basic research studies pointed to the im-
portance of the acetylation and deacetylation reactions not
only at the level of histone lysine residues but also on oth-
ercellularfactorswhichtogethercouldaﬀectgeneexpression
regulation. In fact, although the pioneering studies focused
on the role of histone acetylation in the control of gene tran-
scription, recent investigations have pointed to the notion
that reversible nonhistone proteins acetylation is an impor-
tant posttranslational modiﬁcation that regulates a wide
range of cellular functions, including protein stability, pro-
tein-protein interactions, and the recognition of DNA by
proteins [1]. Although this might be regarded as an oversim-
pliﬁcation, the acetylation and deacetylation could be con-
sidered as a molecular “on-oﬀ” switch. Indeed, in the di-
verse molecular complexes involving the deacetylases, the re-
versible acetylation may have either positive or negative ef-
fect, depending on the gene involved [2].
STRUCTURAL AND FUNCTIONAL DIVERSITIES OF
HISTONE DEACETYLASES
A major breakthrough in the characterization of histone
deacetylases came with the cloning of HDAC1 encoding gene
[3]. Further studies revealed the existence of a large family
of proteins in higher eukaryotes similar to the yeast RPD3
protein, a known factor involved in gene transcription regu-
lation [4], suggesting for the ﬁrst time the link between the
histone deacetylation and transcriptional control. This large
familycomprisesHDAC1,HDAC2,HDAC3,andHDAC8ex-
hibiting high sequence identity and similar domain organi-
zation, and thus grouped as class I HDACs. Given that the
yeast cells express another histone deacetylase, a complex
with the active part carried by the HDA1 catalytic subunit
[5] and the search for homologs in vertebrates allowed the
identiﬁcationofHAD1-likeproteins,ﬁrstinmouse:mHDA1
and mHDA2 [6], then in human: HDAC4, HDAC5, HDAC6,
HDAC7, and HDAC9 [7–9]. Therefore, this family of en-
zymes was grouped as class II deacetylases. A third class of
deacetylases (class III) comprises the SIR2 (silent informa-
tion regulator)-like family of NAD-dependent deacetylases2 Journal of Biomedicine and Biotechnology
[1]. The SIR2 gene family members have been cloned from a
variety of species ranging from bacteria to man indicating a
high degree of conservation throughout evolution [10]. SIR2
was ﬁrstly described in budding yeasts to be involved with
SIR3 and SIR4 proteins in transcriptional repression, or si-
lencing, by modulating chromatin structure at mating-type
loci (HML and HMR) and subtelomeric regions [11].
The protein encodedby the SIR2 genebelongs to a highly
conserved family of closely related proteins in both prokary-
otic and eukaryotic species named Hst proteins (Homolo-
gous of Sir two) or sirtuins. Based on their primary struc-
ture, the family could be divided into ﬁve classes [12]. The
yeast Saccharomyces cerevisiae has, in addition to the found-
ing member SIR2, four homologs (Hst 1–4) belonging to
class I proteins. Eight sirtuins have been identiﬁed in human
(SIRT1-8) [12, 13]. Human SIR-T1, SIR-T2, and SIR-T3 be-
long to class I, SIR-T4 is in class II, SIR-T5 is in class III,
and SIR-T6 and SIR-T7 are in class IV sirtuins. SIR-T8 re-
cently identiﬁed in thyroid carcinoma cell lines and tissues
[13] shared 85% identity in the core sirtuin domain to the
SIR-T7, and thus could be included in class IV. Several bac-
teria species have also sirtuins being all of class III. An inter-
mediate class between classes II and III or classes I and IV is
designed class U which comprises few gram-positive bacte-
rial and Thermatoga maritima sirtuins [12].
Transcriptional repression is directly associated with the
recruitment of multiprotein complexes containing histone
deacetylases. The Yin Yan 1 (YY1), Mad/Max heterodimer,
and the nuclear hormone receptors represent paradigms of
transcriptional repressors [14]. The YY1 has been shown to
interact with class I HDACs in vitro and in vivo. The HDAC1
and HDAC2 were immunoprecipitated with a mouse pro-
tein mSin3a which is known to bind to Mad. Other stud-
ies have shown that Sin3a-HDAC complex contains multi-
plecomponentsincluding histone-binding proteins.HDAC1
and HDAC2 were also found in association with multipro-
tein complexes known as NuRD/Mi2/NRD [15].
The HDAC3 has a distinguishable feature compared to
HDAC1 and HDAC2 that is the shuttling between the nu-
cleus and the cytoplasm [16]. The enzyme was not found
in association with either Sin3/HDAC or NuDR/Mi2/NDR
complexes; instead, its function seems to be linked to the ac-
tivityofmultiproteincomplexescontainingthenuclearcore-
pressor(NCoR)[17].Althoughsomeofthefunctionsofclass
II deacetylases (HDAC4, HDAC5 and HDAC7) seem to be
shared with class I members, they are not found in associa-
tion with the two well-characterized deacetylase complexes:
Sin3/HDAC and NuRD/Mi2/NRD. Furthermore, a particu-
lar characteristic of all members of class II HDACs is their
nucleocytoplasmic shuttling.
Unlike the other class I and class II HDACs, sirtuins re-
quire NAD as a cofactor. The SIR2 protein of yeast is the
founding member of a large family of NAD-dependent
HDACs. In yeast, the SIR2 gene is involved in the regulation
of transcriptional silencing, DNA damage responses, and
lifespan extension mediated by caloric restriction [18, 19].
The mammalian SIRT1 gene encodes an NAD-dependent
nuclear HDAC that is the closest structural ortholog of yeast
SIR2 protein [12]. However, the mammalian SIRT1 has been
shown to deacetylate a wide range of nonhistone substrates
comprising TAF168, PCAF, p300, MyoD, p53, and Ku70
[20–23]. Furthermore, recent investigations have shown that
SIRT1 mediates the deacetylation of RelA/p65, a subunit of
the NF-κB transcription factor that regulates a wide range
of cellular processes [24]. SIRTs 2 and 3 are cytoplasmic pro-
teins.SIRT2hasbeenshowntoplayaroleintubulindeacety-
lation, whereas SIRT3 is a mitochondrial protein whose sub-
strate (s) is not yet identiﬁed [25–27]. Therefore, it is possi-
ble that the actual extensive investigations focused on SIR2-
relatedfamilyofproteinswilluncovernewbiochemicalpath-
ways, and thus new targets of these enzymes.
Histonedeacetylasesincancerdiseases
Speciﬁc events-driven changes that led to the cancer devel-
opment and progression are interconnect complex molecu-
lar modiﬁcations including DNA methylation, histone acety-
lation, phosphorylation, ubiquitylation, and ADP ribosyla-
tion. The p53 protein is among the factors that play pivotal
role in gene expression regulation and cell signaling path-
ways’ network that govern the cell decision for life or death.
Mutation of p53 correlates with many forms of cancer [28],
and mice that lack p53 develop normally but rapidly suc-
cumb to cancers [29]. Moreover, low levels of p53 and in-
creased production of Mdm2 protein, the negative regulator
of p53, have been shown to be associated with increased cell
growth and proliferation [30]. Furthermore, recent investi-
gationshavereportedthatoverexpressionofp53incisplatin-
treated tumors might be associated with cell resistance to
apoptosis [31]. In biopsies of involved psoriatic skin, de-
creased expression of p53 could be seen when compared to
uninvolved skin areas, suggesting that the loss of growth-
inhibitory activity due to downregulation of p53 is respon-
sible for the keratinocyte hyperproliferation characteristic of
the disease [32].
At the cellular level, in the absence of stress, p53 is not
phosphorylated and linked to Mdm2 which directed the
protein to the proteasome degradation pathway (Figure 1),
a number of posttranslational modiﬁcations among which
acetylation and deacetylation play a role in the activation
of p53 [33]. Under stress conditions, its phosphorylation
and release from Mdm2 and further acetylation led to its
activation, inducing checkpoints in the cell-division cycle,
permanent cell-division arrest (senescence), and cell death
(Figure 1). The activity of acetylase remodeling complex-
associated p53 may lead to “open chromatine” conﬁgura-
tion and binding of transcriptional factors and mediators
(Figure 2(a)). However, there are increasing lines of evi-
dences indicating that deacetylases can contribute in the reg-
ulation of p53 activity. Indeed, the transcriptional repres-
sion of certain genes has been shown to involve p53 asso-
ciation with other molecular complexes containing mSin3A
(a corepressor), a factor termed PID identical to metastasis-
associated protein 2 (MTA2), and HDAC1 (Figure 2(b)).
Furthermore, recognition of substrates other than histonesM. Ouaissi and A. Ouaissi 3
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Figure 1: Schematic representation of some modiﬁcations aﬀecting p53 leading to cell growth and proliferation or death. (a) Under stress
conditions, phosphorylation of p53 and release from Mdm2 and further acetylation led to p53 activation; (b) mutations of p53 and the
modiﬁcations in the levels of p53/Mdm2 might aﬀect cell growth and proliferation.
by SIR2 family of proteins has broad implications in im-
portant biological processes. In fact, the ability of class III
deacetylases to physically interact and modify the function
and biological properties of proteins such as p53 [34, 35]
and tubulin [36] has made them a paradigm for the inves-
tigation of new biochemical pathways involved in tumore-
genesis. Thus, the selective binding of acetylases or HDAC
might determine whether p53 will mediate the activation or
repression of transcription (Figures 2(a) and 2(b)). There-
fore, on account of their interaction with various molecu-
lar complexes involved in gene expression, HDACs have cap-
tured the attention of a large number or researchers.
The potential implication of HDAC in tumorigenesis has
beenwelldocumented[25].Anumberofreportshaveshown
HDACs to be overexpressed in various tumor cells [37, 38].
HDACs were also found to be overexpressed under certain
circumstances such us hypoxia, hypoglycemia, and serum
deprivation[39].InthecaseofclassIIIdeacetylasemembers,
there are several recent reports showing either up- or down-
regulation of SIRTs genes. For instance, isolation of an SIR-
like gene, SIR-T8, that is overexpressed in thyroid carcinoma
andcelllines butnot inadenomashasbeenrecentlyreported
[13]. Unexpectedly, in contrast to most SIR proteins which
may be part of the telomere/telomerase functional complex,
which is localized to the nucleolus [40], SIR-T8 is in the cy-
toplasm under the nuclear membrane. Moreover, in the case
of human gliomas among diﬀerentially expressed genes evi-
denced by a proteomics-based approach, the SIRT2 gene was
shown to be downregulated [26] suggesting that SIRT2 may
serve as a novel molecular marker for gliomas. Interestingly,
ectopic expression of SIRT2 gene induced cell-growth sup-
pression in glioma cell lines having barely detectable endoge-
nous SIRT2 levels. These observations allowed the authors to
suggest SIRT2 being a tumor suppressor gene in glioma cells
through tubulin acetylation and consequently microtubule
organization.
Other important targets of HDACs are members of the
nuclear factor Rel/NF-κB family known to be made of a
plethora of transcriptional regulators sharing the so-called
Relhomologydomain[41].Infact,NF-κBhasbeenshownto
be activated in the early malignant transformation of mam-
mary cells of the breast [42]. Moreover, NF-κBi sc o n s t i t u -
tively active in pancreatic adenocarcinoma in humans [43],
in T leukemia lymphocytes [44], in human breast cancer
[45], and in head and neck squamous carcinoma cell lines
[46], therefore facilitating cell survival and tumor progres-
sion by activating biochemical pathways leading to the in-
hibition of apoptosis process. Once in the nucleus, the NF-
κBassociateswithhistoneacetyltransferasescontainingcom-
plexes [47]. Acetylation of NF-κB RelA/p65 and p50 sub-
units aﬀects both its DNA binding ability and transcrip-
tional activity [48, 49]( Figure 2(a)). Deacetylation of NF-
κB RelA/p65 subunit by HADC1, HDAC2 [50], or HDAC3
[51] induced increased IκBα association leading to loss of
NF-κB transactivation capacity (Figure 2(b)). Moreover, re-
cent investigations have shown that SIRT1, a member of
class III deacetylases, represses NF-κBf u n c t i o nb yd e a c e t y -
lating the RelA/p65 lysine 310 [52], regulating therefore its
antiapoptotic activity.Thus,HDACs seemtobekeyelements
in the regulation of gene expression, diﬀerentiation and de-
velopment, and the maintenance of homeostasis. Their as-
sociation with a number of cellular oncogenes and tumor
suppressor genes make them candidate targets for anticancer
drugs and therapies.4 Journal of Biomedicine and Biotechnology
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Figure 2: Roles of acetylation/deacetylation of p53 and NF-κB in transcriptional regulation. (a) Interaction of p53 with acetylases facilitates
alteration of chromatine structure by histone acetylation and association of transcription complex machinery; p53 is itself subject to acety-
lation. NF-κB becomes attached to acetyltransferases containing complexes facilitating an “open chromatin” conﬁguration and the binding
of transcription factors and RNA polymerase II. (b) Deacetylases regulate p53 and NF-κB- mediated transcription, possibly by inducing a
“repressed chromatin” conﬁguration.
Histonedeacetylaseinhibitorsandcancertherapy
The HDAC inhibitors (HDIs) by releasing trancriptional
repression-induced cell cycle arrest, diﬀerentiation, and/or
apoptosis of diﬀerent tumors are an interesting strategy for
antitumor chemotherapy development [27]. The p53 may
play an important role in HDIs-mediated growth inhibition.
Indeed, it has been shown that although the sodium bu-
tyrate (NaB) induced the inhibition of DNA synthesis both
in the presence or absence of p53, the levels of cell detah by
apaoptosis are greatly reduced in the absence of p53 [53].
Nevertheless, there are other mechanisms not involving p53
by which HDIs function. For instance, in the absence of p53,
the trichostatin A (TSA), a natural product isolated from
Streptomyces hygroscopicus, used initially as an antifungal an-
tibiotic, causes cell cycle arrest at the G2/M phase transi-
tion leading to cell death by apoptosis [54]. Furthermore,
fusion proteins that utilize HDACs have been implicated in
many acute leukemias [55]. In fact, in normal conditions
and in the absence of retinoic acid (RA), retinoic acid re-
ceptor α (RARα) binds to DNA as a heterodimer with an
RXR (retinoid-X receptor) in complex with transcriptionalM. Ouaissi and A. Ouaissi 5
corepressor containing NcoR, Sin3A, and HDAC. The pres-
enceofRAinducedthedisplacementofthecorepressorcom-
plex which is replaced by a coactivator complex containing
HAT (p300/CBP and PCAF). In certain acute promyelocytic
leukemia (APL), a chromosomal translocation of t(11;17)
fuses a large portion of the RARα to a coding sequence of
a promyelocytic leukemia zinc ﬁnger (PLZF) protein ren-
dering the RARα insensitive to physiological levels of RA
leading to the blockage of hematopoietic cells diﬀerentia-
tion and their proliferation without restraint [56]. The TSA
is the most potent of the known HDACs class I and class
II inhibitors that restore the capacity of leukemic cells car-
rying PLZF-RARα to respond to pharmacological doses of
all-trans-retinoid acid [56–58]. Thus, HDIs by interfering
with fusion protein-induced blockage of diﬀerentiation of
hematopoietic cells relieve the repression of diﬀerentiation
gene transcription allowing the cells to respond to RA. Based
on the structure of TSA, a large number of synthetic drugs
weredesigned.Theypossessa“cap”group,acentralaliphatic
chain, and a functional group that would chelate the zinc
cation in the active site in HDAC. Various compounds have
been tested in cell cultures and in preclinical murine mod-
els, several are currently under phase I/II clinical trials [59].
Hydroxamic acid derivatives represent eﬃcient inhibitors of
both HDAC class I and class II enzymes, with activities in
vitro detected at nanomolar to micromolar concentrations.
One of the potential problem is their reversible activity to-
wards class I and class II enzymes. For instance, TSA, one
of the ﬁrst HDIs containing a hydroxamic functional group,
inhibits the growth of pancreatic adenocarcinoma cells and
induced ACHN renal carcinoma cell cycle arrest. Suberoy-
lanilide hydroxamic acid and pyroxamide are compounds
inducing growth arrest, diﬀerentiation and/or apoptosis in
a wide range of tumor cells. A number of natural products
such as apicidin, a cyclic tetrapeptide generated from the en-
dophytic fungi, Fusarium pallidoroseum, are able to inhibit
HDACs and the growth of tumor cells. In fact, a number of
genes that are consistently upregulated have their promoters
associated with acetylated histones. One such gene encodes
thecyclin-dependentkinase(CDK)inhibitorp21WAF1,which
inhibits cell cycle progression by blocking CDK activity and
arrests the cell cycle in G1 phase. Most of the HDIs induce
expression of p21, and apicidin had also similar eﬀect being
therefore able to block tumor cell proliferation [59]. More-
over, a compound, the FK228 a bicyclic depsipeptide de-
rived from Chromobacterium violaceum, inhibits HDACs at
nanomolar concentrations and exerts potent antitumor ac-
tivity byinducing apoptosis celldeath.Moreover,theFK228-
induced HDAC inhibition led to increased expression of
angiogenic-inhibitory factor encoding gene and suppression
of gene encoding the angiogenic-stimulating factor interfer-
ingthereforewiththeneovascularizationrequiredforcertain
tumor growth.
Thus, most of these HDIs act by interfering with cell cy-
cle, diﬀerentiation, and apoptosis pathways depending on
the nature of tumor cells (Figure 3). In fact, key regula-
tors such as NF-κB as described above are target of HDACs.
For instance, a link between inﬂammation and susceptibility
to cancer has been already evidenced in population studies
[60]. In precancerous cells, NF-κB by increasing the expres-
sion of proinﬂammatory and survival genes and inhibiting
death-promoting pathway may enhance premaligant poten-
tial. HDIs by preventing NK-κB transactivation may enable
the reexpression of silenced genes in tumor cells leading to
the reversion of the malignant phenotype exerting therefore
a therapeutic eﬀect.
It is also noteworthy that HDIs could potentiate the ef-
fect of antitumor drugs. Indeed, it has been shown that co-
incubation of human leukemia cells (K562) with a protea-
some inhibitor, the bortezomid, and HDIs (suberoylanilide
hydroxamid acid or sodium butyrate) resulted in increase of
mitochondrialinjuryandapoptosis[61].Moreover,pretreat-
ment of human leukemic cells with MS-275, an orally active
synthetic benzamidine derivative that belongs to HDIs, sig-
niﬁcantly enhanced the activity of the cytotoxic drug, Flu-
darabine, a purine analogue that has demonstrated signiﬁ-
cant activity in B-cell malignancies [62].
The enzymatic reaction of sirtuins involved nicotine ade-
nine dinucleotide (β-NAD) and the N-acetylated substrate.
The ﬁnal reactions products comprise the deacetylated prod-
uct, the nicotinamide (Nam), and 2 -O-acetyl-ADP-ribose.
A feedback regulation of sirtuin activity is exerted by Nam.
Indeed, Nam has been reported to be a physiological in-
hibitor of certain deacetylase SIR2 enzymes such as the yeast
(ySIR2) and human SIRT1 [63]. Moreover, it is noteworthy
that Nam was able to reduce inﬂammation in the case of pa-
tients suﬀering from osteoarthritis [64] and it is in trials as a
therapy to prevent cancer recurrence and insulin-dependent
(type I) diabetes [65].
Parasitichistonedeacetylases
Although the cancer is not a single disease, the growth of the
parasites in their host and that of cancer cells share at least
one common feature that is their mutual capacity for rapid
cell division. Moreover, we have recently attempted to delin-
eatesomesimilaritiesbetweentheimmuneevasionstrategies
that parasites and tumors employ [66]. The protozoan para-
sites which cause important diseases in human and a num-
ber of other mammalian species have complex life cycles in-
cluding diﬀerent developmental stages. Most of these para-
sites are transmitted by insect vectors and invade a range of
diﬀerent tissues in their mammalian hosts. These series of
transitions involve major modiﬁcations in morphology, gene
expression, and cell cycle in order to survive environmen-
tal extremes such as toxic metabolites and acidic pH of the
host cell phagolysosomes. Therefore, cells at diﬀerent peri-
ods of the life cycle may diﬀer signiﬁcantly. Gene expression
determines the state of diﬀerentiation and has a role in the
regulation of activity of a given parasite form under a phys-
iological state. The importance of HAT and HDACs in the
life cycle of pathogenic protozoan parasites is only partially
emerging. Thus, recent investigations have shown that like
other eukaryotes, the protozoan parasites possess HATs and
HDACs orthologues and the reversible acetylation seems to
play a key role in gene transcriptional regulation and cell cy-
cle progression.6 Journal of Biomedicine and Biotechnology
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Figure 3: A schematic model for HDIs mode of action. Complex molecular interactions involve acetylation and deacetylation events of
histone in the vicinity of promoters and of nonhistone proteins, such as transcription factor p53. Acetylation and deacetylation aﬀect cell
cycle transition through regulation of proteins such as p21WAF1 and cyclin B1. The pathways could be dependent on or independent of p53.
Indeed, the African trypanosome, Trypanosoma brucei,
whichgrowsinthemammalianvasculatureandcausessleep-
ing sickness in humans and Nagana in cattle, expresses four
H D A C so r t o l o g u e sn a m e dD A C 1 – 4[ 67]. The DAC1 and
DAC2 share signiﬁcant similarity with mammalian and yeast
class I HDACs, whereas DAC3 and DAC4 are closely re-
lated to class II deacetylases. Despite the fact that none of
the four genes were present among the > 5000 Tb r u c e iex-
pressed sequence tags, RT-PCR analysis showed that the four
genes were expressed in bloodstream parasites as well as in
insect developmental stages. Functional analysis of DAC1–
4 genes by reverse genetic approach showed that DAC1 and
DAC3 appear to be essential, whereas DAC2 and DAC3 are
not required for parasite viability. In a more recent study,
an unusual member of the SIR2 family, the TbSIR2RP1,
with both histone NAD-dependent deacetylase and ADP-
ribosyltransferase activities, has been identiﬁed in Tb r u -
cei [68]. The parasite resistance to DNA damage correlates
with the level of TbSIR2RP1 expression. The authors sug-
gest that histone modiﬁcation (deacetylation/ribosylation)
by TbSIR2RP1 is involved in DNA repair.
In the case of Plasmodium falciparum, a member of the
apicomplexan protozoan family which causes malaria, one
of the leading causes of loss of life worldwide accounting for
over 1.5 million deaths annually, a gene encoding a protein
sharing signiﬁcant homology to yeast, human, and other eu-
karyotic HDACs, and thus termed PfHDAC1, has been char-
acterized[69].ThePfHDAC1mRNAtranscriptwasfoundto
be predominantly expressed in mature asexual blood stages
and in gametocytes and the ∼ = 50kd PfHDAC1 protein local-
ized in the P falciparum nucleus. Furthermore, an expressed
sequencetagforayeastRPD3homologuehasbeenidentiﬁed
in the genome of Cryptosporidium parvum,ap r o t o z o a np a r -
asite having biochemical and cell biological peculiarities but
sharinganumberofmorphologicalandbiochemicalfeatures
with other apicomplexa [70]. Moreover, in recent investiga-
tions, a P falciparum protein homologous to the yeast SIR2
called PfSir2 was found to play a role in chromatin modi-
ﬁcation at telomeres [71]. Indeed, the data reported showed
thatPfSir2proteinlocalizedtotelomericfociandthenucleo-
lus and suggested that the protein generates a hypoacetylated
state of chromosome ends, including subtelomeric var genes,
that represses gene activity.
The Entamoeba histolytica, an intestinal parasite that
infects about 50 million people worldwide, has also been
shown to express both HAT and HDAC activities [72]. Par-
asite proteins ehGCN5 and ehMYST carrying a signature
of acetytranferase domain (GNAT motif, ehGCN5) and a
carboxy-proximal MOZ-SAS domain including a zinc ﬁnger
(the signature of a MYST family) have been characterized.
The HAT assays showed that the ehMYST protein produced
in Ec o l iw a sa b l et oi n c o r p o r a t e[ 3H] from [3H] acetyl-CoA
into calf thymus histones and standard assays revealed the
presence of HDAC activity in Eh i s t o l y t i c anuclear extracts.
Moreover, a single putative gene encoding a member of class
I family named ehHDAC, was characterized at the molecularM. Ouaissi and A. Ouaissi 7
level, although a functional native or recombinant protein
has not been reported.
Leishmania spp, the causative agents of leishmaniasis,
a group of several diﬀerent diseases widely distributed in
tropical and subtropical areas and also are commonly found
in the Mediterranean basin, are kinetoplastid protozoan
transmitted by a blood-feeding dipteran vector of the sub-
family Phlebotominae. These parasites have complex life cy-
cles that include diﬀerent morphological forms. Within the
insect vector, the parasite replicates as a noninfective pro-
mastigote, which transforms into infective metacyclic pro-
mastigote. In the mammalian host, the infective promastig-
otes invade the macrophages and diﬀerentiate into amastig-
otes, which are the proliferative forms within the vertebrate
hosts.
In an earlier report, we described the molecular char-
acterization of several Lm a j o rproteins eluted from gluta-
thione-agarosecolumn[73].Furtherstudiesallowedtoshow
that one member of this group is among members of SIR2
family and thus was termed LmSIR2 [74]. A gene encod-
ing homologous protein in L infantum, exhibiting NAD+-
dependent deacetylase activity, was sequenced and termed
LiSIR2 [75] and other related sequences can be found in the
Leishmaniagenomedatabase[Lmajorsirtuin(CAB55543),L
major cobB (LmjF34.2140)]. The expectation was to ﬁnd the
LmSIR2 associated with the nucleus, instead, the protein had
a cytoplasmic localization [76]. However, further indepen-
dentinvestigationsrevealedthepresenceofSIR2-relatedpro-
teins in the cytoplasm of diﬀerent species, and in the mito-
chondria [11]. Interestingly, L infantum amastigotes, the ver-
tebrate stage of the parasite, carrying extracopies of LmSIR2
or L infantum SIR2 (LiSIR2) gene, when maintained under
normal axenic culture conditions, showed striking increase
in the survival due to an inherent resistance to apoptosis-like
death, leading to a longer stationary phase of growth [75]. In
a more recent study, it has been demonstrated that although
L infantum tolerates deletion of one wild-type LiSIR2 allele,
deletion of both genes is a lethal event, indicating that at
least one active LiSIR2 gene is required for parasite survival.
Monoallelic disruption of LiSIR2 (LiSIR2+/−) resulted in the
obtention of L infantum lines with signiﬁcantly reduced vir-
ulence in vitro and in vivo [77]. Although it remains to be
demonstrated that a protein with a cytoplasmic localization
could inﬂuence nuclear silencing events, it is reasonable to
assume that inhibiting parasite SIR2 activity may represent a
mean to interfere with parasite development.
Histonedeacetylaseinhibitorsinterferewith
parasitedevelopment
Several studies using various pharmacological HDIs and dif-
ferent parasite species have concluded that HDACs play a
critical role in the life cycle of theses organisms. It has been
shown,forexample,thatapicidinexertedanantiparasiticac-
tivity against the apicomplexan family of protozoa, including
P falciparum, Cp a r v u m , Toxoplasma gondii, Sarcocystis neu-
rona,a n dEimeria tenella [78]. The antiparasitic activity of
apicidin appears to be attributable to inhibition of apicom-
plexa HDAC at nanomolar concentrations. Furthermore, re-
cent investigations conducted on Neospora caninum,ap r o -
tozoan parasite closely related to Tg o n d i i , that infects a wide
range of vertebrate hosts (ie, cattle, sheep, goats, horses, and
dogs) have shown that apicidin exerted antiparasitic activity
through the inhibition of HDACs [79]. Another structurally
unrelated compound, depucidin, a natural product isolated
from Altermaria brassiciola, when used in an in vitro culture
system at a deﬁned concentration, inhibited signiﬁcantly the
intracellular multiplication of Nc a n i n u mtachyzoites with-
out exerting any cytotoxicity toward the host Vero cells. The
inhibitory eﬀect seems to be related to the parasite HDAC
inhibition. Moreover, the amebic trophozoites ehHDAC ac-
tivity could be completely inhibited in the presence of low
concentration of the HDI inhibitor TSA, a feature shared by
the classical HDAC enzymes.
In more recent studies, it has been reported that Sirti-
nol, a commercially available inhibitor of SIR2 deacetylases,
induced the death of L infantum amastigotes, the vertebrate
stage of the parasites; whereas, the promastigotes, the insect
stage forms, were insensitive [80]. Interestingly, amastigotes
which overexpress SIR2 were less sensitive to the drug. This
might be related to stage-speciﬁc requirement for functional
SIR2 enzyme. Indeed, molecular biological manipulation of
LinfantumSIR2genebyhomologousrecombinationallowed
to show that single LiSIR2 gene disruption (LiSIR+/−)d o e s
not aﬀect the growth of parasite in the promastigote form,
whereas axenic amastigotes display a marked reduction in
their capacity to multiply in vitro inside macrophages and
in vivo in Balb/c mice [77]. Furthermore, Nam, a physio-
logical inhibitor of certain deacetylase SIR2 enzymes, has
been shown to exert an antimicrobial and antiviral activi-
ties against Mycobacterium tuberculosis and human immun-
odeﬁciency virus, respectively [81]. In addition, recent in-
vestigations have also demonstrated that Nam could express
antiparasitic activity in vitro on various Leishmania species
[82]. However, although Nam could inhibit NAD-dependent
deacetylase activity contained in the extracts from parasites
overexpressing SIR2 enzyme, the mutant parasites were as
sensitivetoNamactivityastheparentalwild-typeclone,sug-
gesting therefore that Nam may interfere with other para-
site metabolic pathways in addition to those involving NAD-
dependent SIR2 deacetylase activity.
Another aspect to be taken with care is the possible mod-
ulation of host cell transcription machinery by the para-
site itself. One fascinating example is that of T cruzi and
host cell NF-κB. The NF-κB plays an important role in the
coordination of innate and acquired immune cellular re-
sponses during microbial infections. T cruzi has a marked
tissue tropism with preference for infection of myocytes. It
has been demonstrated that NF-κB activation plays a role in
controlling intracellular infection in nonimmune cells [83].
Indeed, trypomastigotes, the vertebrate host infective stage
of T cruzi, activate nuclear translocation and DNA binding
of NF-κB p65 subunit and NF-κB-dependent gene expres-
sion in epithelial cells, endothelial cells, and ﬁbroblasts. In-
ducible expression of the inhibitory mutant IκBαm leading
to the inactivation of epithelial cell NF-κB induced increased8 Journal of Biomedicine and Biotechnology
parasiteinvasion.Incontrast,TcruzidoesnotactivateNF-κB
in cells derived from skeletal, smooth, or cardiac muscle re-
sultinginincreasedlevelofcellinfection.Therefore,interfer-
ing with NF-κB activation through the use of indiscriminate
HDIsmayhavedramaticconsequencesonthelevelofTcruzi
invasion.
CONCLUDING REMARKS
The dynamic remodeling of chromatin is a complex process
that governs gene expression relevant to cell division, diﬀer-
entiation,ordeath.Manymoleculardetailsareemergingand
shed light on the key role of the deacetylase enzymes in the
modiﬁcation of chromatin structure leading to altered ac-
cessibility of certain genes. Given the degree of homology
between members of this large family of enzymes and the
putative redundancy of their functions, pharmacological in-
hibitorsmayhavelimitedselectivityorspeciﬁcityleadingtoa
functional consequence which is the toxicity against normal
tissues. However, studies of enzymatic activities of members
ofthesamefamily,forinstancehumansirtuins,usinghistone
H4 peptide, revealed low or undetectable activity [84]. This
could reﬂect biochemical peculiarities (ie, substrate speci-
ﬁcities, cofactors requirement) features that perhaps may be
exploitable for drug design. The resolution of the catalytic
core structures of a number of enzymes and their substrate-
bound complex would allow the design of speciﬁc inhibitors
with potential therapeutic eﬃcacy in cancer and parasitic
diseases.
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